| Loss of PTEN promotes resistance to T cell–mediated immunotherapy W Peng, JQ Chen, C Liu, S Malu, C Creasy, MT Tetzlaff, C Xu, ... Cancer discovery 6 (2), 202-216, 2016 | 1297 | 2016 |
| Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy J Gao, LZ Shi, H Zhao, J Chen, L Xiong, Q He, T Chen, J Roszik, ... Cell 167 (2), 397-404. e9, 2016 | 1123 | 2016 |
| A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade L Jerby-Arnon, P Shah, MS Cuoco, C Rodman, MJ Su, JC Melms, ... Cell 175 (4), 984-997. e24, 2018 | 932 | 2018 |
| Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients LG Radvanyi, C Bernatchez, M Zhang, PS Fox, P Miller, J Chacon, R Wu, ... Clinical Cancer Research 18 (24), 6758-6770, 2012 | 433 | 2012 |
| Increased tumor glycolysis characterizes immune resistance to adoptive T cell therapy T Cascone, JA McKenzie, RM Mbofung, S Punt, Z Wang, C Xu, ... Cell metabolism 27 (5), 977-987. e4, 2018 | 428 | 2018 |
| Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16–related cancer: a phase 2 clinical trial E Massarelli, W William, F Johnson, M Kies, R Ferrarotto, M Guo, L Feng, ... JAMA oncology 5 (1), 67-73, 2019 | 384 | 2019 |
| Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial T Cascone, WN William Jr, A Weissferdt, CH Leung, HY Lin, A Pataer, ... Nature medicine 27 (3), 504-514, 2021 | 369 | 2021 |
| Oncogenic BRAF (V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma JS Khalili, S Liu, TG Rodríguez-Cruz, M Whittington, S Wardell, C Liu, ... Clinical Cancer Research 18 (19), 5329-5340, 2012 | 315 | 2012 |
| Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook R Wu, MA Forget, J Chacon, C Bernatchez, C Haymaker, JQ Chen, P Hwu, ... The Cancer Journal 18 (2), 160-175, 2012 | 294 | 2012 |
| Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer J Blando, A Sharma, MG Higa, H Zhao, L Vence, SS Yadav, J Kim, ... Proceedings of the National Academy of Sciences 116 (5), 1692-1697, 2019 | 260 | 2019 |
| Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues ER Parra, N Uraoka, M Jiang, P Cook, D Gibbons, MA Forget, ... Scientific reports 7 (1), 13380, 2017 | 242 | 2017 |
| Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study. T Cascone, WN William, A Weissferdt, HY Lin, CH Leung, BW Carter, ... Journal of Clinical Oncology 37 (15_suppl), 8504-8504, 2019 | 193 | 2019 |
| Identification of bacteria-derived HLA-bound peptides in melanoma S Kalaora, A Nagler, D Nejman, M Alon, C Barbolin, E Barnea, ... Nature 592 (7852), 138-143, 2021 | 190 | 2021 |
| A first-in-human study and biomarker analysis of NKTR-214, a novel IL2Rβγ-biased cytokine, in patients with advanced or metastatic solid tumors SE Bentebibel, ME Hurwitz, C Bernatchez, C Haymaker, CW Hudgens, ... Cancer discovery 9 (6), 711-721, 2019 | 180 | 2019 |
| Bempegaldesleukin (NKTR-214) plus nivolumab in patients with advanced solid tumors: phase I dose-escalation study of safety, efficacy, and immune activation (PIVOT-02) A Diab, NM Tannir, SE Bentebibel, P Hwu, V Papadimitrakopoulou, ... Cancer discovery 10 (8), 1158-1173, 2020 | 175 | 2020 |
| TCR repertoire intratumor heterogeneity in localized lung adenocarcinomas: an association with predicted neoantigen heterogeneity and postsurgical recurrence A Reuben, R Gittelman, J Gao, J Zhang, EC Yusko, CJ Wu, R Emerson, ... Cancer discovery 7 (10), 1088-1097, 2017 | 167 | 2017 |
| Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function JA Hernandez-Chacon, Y Li, RC Wu, C Bernatchez, Y Wang, JS Weber, ... Journal of immunotherapy 34 (3), 236-250, 2011 | 156 | 2011 |
| Comprehensive T cell repertoire characterization of non-small cell lung cancer A Reuben, J Zhang, SH Chiou, RM Gittelman, J Li, WC Lee, J Fujimoto, ... Nature communications 11 (1), 603, 2020 | 155 | 2020 |
| BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma SD Bradley, Z Chen, B Melendez, A Talukder, JS Khalili, ... Cancer immunology research 3 (6), 602-609, 2015 | 155 | 2015 |
| Genetic and molecular characterization of uveal melanoma cell lines KG Griewank, X Yu, J Khalili, MM Sozen, K Stempke‐Hale, C Bernatchez, ... Pigment cell & melanoma research 25 (2), 182-187, 2012 | 131 | 2012 |
